The U.S. Food and Drug Administration approved Deciphera Pharmaceuticals Inc.’s Qinlock (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Dr. Reddy’s Laboratories Ltd. received approval for Elyxyb (celecoxib oral solution 25 mg/mL) from the U.S. Food and Drug Administration for the acute treatment of migraine with or without aura in adults.
Bristol Myers Squibb’s Zeposia (ozanimod) won approval from the U.S. Food and Drug Administration as a new treatment for a type of multiple sclerosis.
In a second research report published this year so far, investigators found that the U.S. Food and Drug Administration (FDA) is approving drugs faster than ever.
Changes in U.S. Food and Drug Administration procedures meant to speed approvals for medications may have resulted in less exacting standards, a new analysis suggests.